Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2007-12-25
2007-12-25
Nashed, Nashaat T. (Department: 1656)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C435S219000, C435S226000
Reexamination Certificate
active
11479214
ABSTRACT:
Frozen and lyophilized compositions for a metalloproteinase fibrinolytic agent (fibrolase or NAT), a method for preparing the lyophilized composition, and a kit and method for reconstituting the lyophilized composition are described herein.
REFERENCES:
patent: 4083961 (1978-04-01), Dussourdd'Hinterland et al.
patent: 4447236 (1984-05-01), Quinn
patent: 4610879 (1986-09-01), Markland et al.
patent: 4692139 (1987-09-01), Stiles
patent: 4755167 (1988-07-01), Thistle et al.
patent: 4812405 (1989-03-01), Lair et al.
patent: 4818700 (1989-04-01), Cregg et al.
patent: 4837148 (1989-06-01), Cregg
patent: 4855231 (1989-08-01), Stroman et al.
patent: 4885242 (1989-12-01), Cregg
patent: 5167628 (1992-12-01), Boyles
patent: 5222941 (1993-06-01), Don Michael
patent: 5250034 (1993-10-01), Appling et al.
patent: 5370653 (1994-12-01), Cragg
patent: 5380273 (1995-01-01), Dubrul et al.
patent: 5498236 (1996-03-01), Dubrul et al.
patent: 5626564 (1997-05-01), Zhan et al.
patent: 5709676 (1998-01-01), Alt
patent: 5830468 (1998-11-01), Bini
patent: 5865178 (1999-02-01), Yock
patent: 5922322 (1999-07-01), Bini
patent: 5951981 (1999-09-01), Markland, Jr. et al.
patent: 6020181 (2000-02-01), Bini
patent: 6107280 (2000-08-01), White et al.
patent: 6455269 (2002-09-01), Toombs
patent: 6759431 (2004-07-01), Hunter et al.
patent: 2002/0081685 (2002-06-01), Fox et al.
patent: 0 323 722 (1989-07-01), None
patent: 0 438 200 (1991-07-01), None
patent: 0 624 642 (1994-11-01), None
patent: 0 689 843 (1996-01-01), None
patent: WO 90/07352 (1990-07-01), None
patent: WO 96/36227 (1996-11-01), None
patent: WO 98/24917 (1998-06-01), None
patent: WO 98/46771 (1998-10-01), None
patent: WO 01/24817 (2001-04-01), None
patent: WO 01/25445 (2001-04-01), None
patent: WO 02/12283 (2002-02-01), None
No authors listed, “Results of a Prospective Randomized Trial Evaluating Surgery Versus Thrombolysis for Ischemia of the Lower Extremity,” The Site Trial, Stile Investigators Appendix A, Annals of Surgery, 220(3):251-266 (1994).
Ahmed et al., “Biochemical Characteristics of Fibrolase, a Fibrinolytic Protease From Snake Venom,” Haemostasis, 20:147-154 (1990).
Ahmed et al., “Biochemical and Thrombolytic Properties of Fibrolase—A New Fibrinolytic Protease From Snake Venom,” Haemostasis, 20:334-340 (1990).
Anai et al., “Inhibition of a Snake Venom Hemorrhagic Metalloproteinase by Human and Rat Alpha-Macroglobulins,” Toxicon: Official Journal of the International Society on Toxinology , 36(8):1127-1139 (1998).
Barrett, A.J. (ed) Methods in Enzymology, Academic Press, Inc., Philadelphia, PA, 737-754 (1981).
Bode et al., Astacins, Serralysins, Snake Venom and Matrix Metalloproteinases Exhibit Identical Zinc-Binding Environments (HEXXHXXGXXH and Met-Turn) and Topologies and Should be Grouped Into a Common Family, the ‘Metzincins’, FEBS Lett., 331(1-2):134-140 (1993).
Carpenter et al., “Interaction of Stabilizing Additives With Proteins During Freeze-Thawing and Freeze-Drying” Develop. Biol. Standard, 74:225-239 (1991).
Chen, Drug Development and Industrial Pharmacy, 18(11 and 12):1311-1354 (1992).
Guan et al., Archives of Biochemistry and Biophysics, 289(2):197-207 (1991).
Jackson and Claggett,“Antithrombotic Therapy in Peripheral Arterial Occlusive Disease,” Chect, 114:666S-682S (1998).
Kandarpa et al., “Forceful Pulsatile Local Infusion of Enzyme Accelerates Thrombolysis: In Vivo Evaluation of a New Delivery System,” Radiology, 168:739-744 (1981).
Loayza et al., Journal of Chromatography B, pp. 227-243 (1994).
Manning, “Sequence Analysis of Fibrilase, a Fibrinolytic Metalloroteinase FromAgkistrodon contortrix contortrix,” Toxicon, 33(9):1189-1200 (1995).
Markland et al., “Thrombolytic Effects of Recombinant Fibrolase or Apsac in a Canine Model of Carotid Artery Thrombosis,” Circulation, 90(5):2448-2456 (1994).
Markland et al., “Resolution of Isoforms of Natural and Recombinant Fibrinolytic Snake Venom Enzyme Using High Performance Capillary Electrophoresis,” Journal of Liquid Chromatography, 16(1-10):2189-2201 (1993).
Ouriel et al., “A Comparison of Thrombolytic Therapy With Operative Revascularization in the Initial Treatment of Acute Peripheral Arterial Ischemia,” Journal of Vascular Surgery, 19:1021-1030 (1994).
Ouriel et al., “A Comparison of Recombinent Urokinase With Vascular Surgery as Initial Treatment of Acute Arterial Occlusion of the Legs,” New England Journal of Medicine, 338:1105-1111 (1998).
Potempa et al., “Stabilization vs. Degradation ofStaphylococcus aureusMetalloproteinase,” Biochimica et Biophysica Acia, 993:301-304 (1989).
Pretzer et al., “Stability of the Thrombolytic Protein Fibrolase: Effect of Temperature and pH on Activity and Conformation,” Pharmaceutical Research, 8(9):1103-1112 (1991).
Pretzer et al., “Effect of Zinc Binding on the Structure and Stability of Fibriolase, a Fibrinolytic Protein From Snake Venom,” Pharmaceutical Research, 9(7):870-877 (1992).
Randolph et al., Protein Science, Cambridge University Press, pp. 590-600 (1992).
Retzios et al., “Fibrinolytic Enzymes From the Venoms ofAgkistrodon contortrixandCrotalus basiliscus,” Thrombosis Research, 74(4):355-367 (1994).
Rholam et al., “Role of Amino Acid Sequences Flanking Dibasic Cleavage Sites in Precursor Proteolytic Processing—The Importance of the First Residue C-Terminal of the Cleavage Sites,” European Journal of Biochemistry, 227:707-714 (1995).
Selistre de Araujo et al., “Molecular Cloning and Sequence Analysis of CDNAs for Metalloproteinases From Broad-Banded CopperheadAgkistrodon contortrix laticinctus”, Archives of Biochemistry and Biophysics 320(1):141-148 (1995).
Sreekrishna et al., “Strategies for Optimal Sysnthesis and Secretion of Heterologous Proteins in the Methylothrophic Yeast Pichis Pastoris,” Gene, 190:55-62 (1997).
Stocker et al., “The Metzincins-Topological and Sequential Relations Between the Astacins, Adamalysins, Serralysins, and Matrixins (Collagenases Define a Superfamily of Zinc-Peptidases,” Protein Sci., 4(5):823-840 (1995).
Verstraete et al., “Thrombolytic Agents in Development,” Drugs, 50(1):29-42 (1995).
Williams et al., “The Lyophilization of Pharmaceuticals: A Literature Review,” Journal of Parenteral Science and Technology, 38(2):48-59 (1984).
Kendrick Brent S.
Peterson Brian A.
Amgen Inc.
Nashed Nashaat T.
Robins & Pasternak LLP
LandOfFree
Pharmaceutical compositions of fibrinolytic agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions of fibrinolytic agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions of fibrinolytic agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3826554